Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.


Department of Pulmonology, Kepler University Hospital Krankenhausstrasse 9, 4020 Linz, Austria(1). Electronic address: [Email]


To evaluate serum tumor markers (STM) as biomarkers for treatment monitoring and prognosis in advanced non-small cell lung cancer (NSCLC) treated with single-agent PD-1/PD-L1-directed immune checkpoint inhibitor (ICI) therapy.


Biomarker,CYFRA 21-1,Carcinoembryonic antigen,Immunotherapy,Predictor,RECIST,

OUR Recent Articles